Pipeline Overview
Our pipeline includes SYK, FLT3, EGFR mutants (single, double and triple), and FGFR4
signal network related disease pathways. Genosco’s core competence comes from its
know-how in generating selective kinase inhibitor of interest.
signal network related disease pathways. Genosco’s core competence comes from its
know-how in generating selective kinase inhibitor of interest.
Our most advanced pipeline is SKI-O-703, a selective SYK inhibitor for rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE) and idiopathic thrombocytopenic purpura (ITP)
in its clinical phase 2. Our second generation SYK inhibitor to treat peripheral T-cell lymphoma
caused by ITK-SYK, BTK inhibitor-insensitive diffuse large B-cell lymphoma (DLBCL)
will be a desirable asset for immuno-oncology and is in late lead optimization stage. G-801,
an FLT3 inhibitor for acute myeloid leukemia is in clinical phase 1 study. GNS-1480,
an EGFR mutant-selective inhibitor for non-small cell lung cancer
and its metastatic brain cancer is in the late preclinical study.
A selective FGFR4 inhibitor program for hepatocellular carcinoma is in lead optimization stage.
systemic lupus erythematosus (SLE) and idiopathic thrombocytopenic purpura (ITP)
in its clinical phase 2. Our second generation SYK inhibitor to treat peripheral T-cell lymphoma
caused by ITK-SYK, BTK inhibitor-insensitive diffuse large B-cell lymphoma (DLBCL)
will be a desirable asset for immuno-oncology and is in late lead optimization stage. G-801,
an FLT3 inhibitor for acute myeloid leukemia is in clinical phase 1 study. GNS-1480,
an EGFR mutant-selective inhibitor for non-small cell lung cancer
and its metastatic brain cancer is in the late preclinical study.
A selective FGFR4 inhibitor program for hepatocellular carcinoma is in lead optimization stage.